Opposing immunomodulatory roles of prostaglandin D2 during the progression of skin inflammation

Journal of Immunology

Volumn 192, Issue 1, 2014, Pages 459-465

  Sarashina, Hana ^a   Tsubosaka, Yoshiki ^a   Omori, Keisuke ^a   Aritake, Kosuke ^b   Nakagawa, Takayuki ^a   Hori, Masatoshi ^a   Hirai, Hiroyuki ^c   Nakamura, Masataka ^d   Narumiya, Shuh ^e   Urade, Yoshihiro ^b   Ozaki, Hiroshi ^a   Murata, Takahisa ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b OSAKA BIOSCIENCE INSTITUTE   (Japan)

^c BML   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOATTRACTANT RECEPTOR HOMOLOGOUS MOLECULE EXPRESSED ON TH2 CELL; PROSTAGLANDIN D SYNTHASE; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR; PROSTANOID RECEPTOR; PROSTANOID RECEPTOR D; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINEAGE; CONTROLLED STUDY; DERMATITIS; DISEASE COURSE; DISEASE SEVERITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE ACTIVATION; MOLECULAR PATHOLOGY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; WILD TYPE;

EID: 84891112230     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302080     Document Type: Article

References (34)

1. Stock, J. L., K. Shinjo, J. Burkhardt, M. Roach, K. Taniguchi, T. Ishikawa, H. S. Kim, P. J. Flannery, T. M. Coffman, J. D. McNeish, and L. P. Audoly. 2001. The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. J. Clin. Invest. 107: 325-331.
2. Ushikubi, F., E. Segi, Y. Sugimoto, T. Murata, T. Matsuoka, T. Kobayashi, H. Hizaki, K. Tuboi, M. Katsuyama, A. Ichikawa, et al. 1998. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 395: 281-284.
3. Furci, L., D. J. Fitzgerald, and G. A. Fitzgerald. 1991. Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation. J. Pharmacol. Exp. Ther. 258: 74-81.
4. Bingham, C. O., III 2002. Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis. Cleve. Clin. J. Med. 69(Suppl 1): SI5-SI12.
5. Gupta, R. A., and R. N. Dubois. 2001. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 1: 11-21.
6. Qu, W. M., Z. L. Huang, X. H. Xu, K. Aritake, N. Eguchi, F. Nambu, S. Narumiya, Y. Urade, and O. Hayaishi. 2006. Lipocalin-type prostaglandin D synthase produces prostaglandin D2 involved in regulation of physiological sleep. Proc. Natl. Acad. Sci. USA 103: 17949-17954.
7. Eguchi, N., T. Minami, N. Shirafuji, Y. Kanaoka, T. Tanaka, A. Nagata, N. Yoshida, Y. Urade, S. Ito, and O. Hayaishi. 1999. Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. Proc. Natl. Acad. Sci. USA 96: 726-730.
8. Kostenis, E., and T. Ulven. 2006. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol. Med. 12: 148-158.
9. Suzuki, F., H. Hayashi, and O. Hayaishi. 1986. Transport of prostaglandin D2 into brain. Brain Res. 385: 321-328.
10. Fitzpatrick, F. A., and M. A. Wynalda. 1983. Albumin-catalyzed metabolism of prostaglandin D2. Identification of products formed in vitro. J. Biol. Chem. 258: 11713-11718.
11. Kikawa, Y., S. Narumiya, M. Fukushima, H. Wakatsuka, and O. Hayaishi. 1984. 9-Deoxy-delta 9, delta 12-13,14-dihydroprostaglandin D2, a metabolite of prostaglandin D2 formed in human plasma. Proc. Natl. Acad. Sci. USA 81: 1317-1321.
12. Sawyer, N., E. Cauchon, A. Chateauneuf, R. P. Cruz, D. W. Nicholson, K. M. Metters, G. P. O'Neill, and F. G. Gervais. 2002. Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br. J. Pharmacol. 137: 1163-1172.
13. Liston, T. E., and L. J. Roberts, II. 1985. Transformation of prostaglandin D2 to 9 alpha, 11 beta-(15S)-trihydroxyprosta-(5Z,13E)-dien-1-oic acid (9 alpha, 11 beta-prostaglandin F2): a unique biologically active prostaglandin produced enzymatically in vivo in humans. Proc. Natl. Acad. Sci. USA 82: 6030-6034.
14. Beasley, C. R., C. Robinson, R. L. Featherstone, J. G. Varley, C. C. Hardy, M. K. Church, and S. T. Holgate. 1987. 9 alpha,11 beta-Prostaglandin F2, a novel metabolite of prostaglandin D2 is a potent contractile agonist of human and guinea pig airways. J. Clin. Invest. 79: 978-983.
15. Scher, J. U., and M. H. Pillinger. 2005. 15d-PGJ2: the anti-inflammatory prostaglandin? Clin. Immunol. 114: 100-109.
16. Forman, B. M., P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans. 1995. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83: 803-812.
17. Kliewer, S. A., J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann. 1995. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83: 813-819.
18. Ajuebor, M. N., A. Singh, and J. L. Wallace. 2000. Cyclooxygenase-2- derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 279: G238-G244.
19. Angeli, V., D. Staumont, A. S. Charbonnier, H. Hammad, P. Gosset, M. Pichavant, B. N. Lambrecht, M. Capron, D. Dombrowicz, and F. Trottein. 2004. Activation of the D prostanoid receptor 1 regulates immune and skin allergic responses. J. Immunol. 172: 3822-3829.
20. Monneret, G., S. Gravel, M. Diamond, J. Rokach, and W. S. Powell. 2001. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 98: 1942-1948.
21. Hammad, H., H. J. de Heer, T. Soullie, H. C. Hoogsteden, F. Trottein, and B. N. Lambrecht. 2003. Prostaglandin D2 inhibits airway dendritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1. J. Immunol. 171: 3936-3940.
22. Murata, T., K. Aritake, Y. Tsubosaka, T. Maruyama, T. Nakagawa, M. Hori, H. Hirai, M. Nakamura, S. Narumiya, Y. Urade, and H. Ozaki. 2013. Antiinflammatory role of PGD2 in acute lung inflammation and therapeutic application of its signal enhancement. Proc. Natl. Acad. Sci. USA 110: 5205-5210.
23. Murata, T., M. I. Lin, K. Aritake, S. Matsumoto, S. Narumiya, H. Ozaki, Y. Urade, M. Hori, and W. C. Sessa. 2008. Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. Proc. Natl. Acad. Sci. USA 105: 20009-20014.
24. Aritake, K., Y. Kado, T. Inoue, M. Miyano, and Y. Urade. 2006. Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J. Biol. Chem. 281: 15277-15286.
25. Almishri, W., C. Cossette, J. Rokach, J. G. Martin, Q. Hamid, and W. S. Powell. 2005. Effects of prostaglandin D2, 15-deoxy-Delta12,14-prostaglandin J2, and selective DP1 and DP2 receptor agonists on pulmonary infiltration of eosinophils in Brown Norway rats. J. Pharmacol. Exp. Ther. 313: 64-69.
26. Spik, I., C. Brénuchon, V. Angéli, D. Staumont, S. Fleury, M. Capron, F. Trottein, and D. Dombrowicz. 2005. Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse. J. Immunol. 174: 3703-3708.
27. Fujitani, Y., K. Aritake, Y. Kanaoka, T. Goto, N. Takahashi, K. Fujimori, and T. Kawada. 2010. Pronounced adipogenesis and increased insulin sensitivity caused by overproduction of prostaglandin D2 in vivo. FEBS J. 277: 1410-1419.
28. Satoh, T., R. Moroi, K. Aritake, Y. Urade, Y. Kanai, K. Sumi, H. Yokozeki, H. Hirai, K. Nagata, T. Hara, et al. 2006. Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J. Immunol. 177: 2621-2629.
29. Matsuoka, T., M. Hirata, H. Tanaka, Y. Takahashi, T. Murata, K. Kabashima, Y. Sugimoto, T. Kobayashi, F. Ushikubi, Y. Aze, et al. 2000. Prostaglandin D2 as a mediator of allergic asthma. Science 287: 2013-2017.
30. Murata, T., K. Aritake, S. Matsumoto, S. Kamauchi, T. Nakagawa, M. Hori, E. Momotani, Y. Urade, and H. Ozaki. 2011. Prostaglandin D2 is a mast cellderived antiangiogenic factor in lung carcinoma. Proc. Natl. Acad. Sci. USA 108: 19802-19807.
31. Goetzl, E. J., and W. C. Pickett. 1981. Novel structural determinants of the human neutrophil chemotactic activity of leukotriene B. J. Exp. Med. 153: 482-487.
32. Kobayashi, K., Y. Tsubosaka, M. Hori, S. Narumiya, H. Ozaki, and T. Murata. 2013. Prostaglandin D2-DP signaling promotes endothelial barrier function via the cAMP/PKA/Tiam1/Rac1 pathway. Arterioscler. Thromb. Vasc. Biol. 33: 565-571.
33. Hirai, H., K. Tanaka, O. Yoshie, K. Ogawa, K. Kenmotsu, Y. Takamori, M. Ichimasa, K. Sugamura, M. Nakamura, S. Takano, and K. Nagata. 2001. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med. 193: 255-261.
34. Houle, F., and J. Huot. 2006. Dysregulation of the endothelial cellular response to oxidative stress in cancer. Mol. Carcinog. 45: 362-367.